Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 15/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 14/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 14/20 | 0.66 |
| ▸ | PTGIR | P43119 | 3/20 | 0.58 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393263 | 0.91 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13062961 | 0.90 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13017196 | 0.86 | ADRA2A (0.81) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| Hydrochloric Acid SCHEMBL4692792 | 0.84 | ADRA2A (0.78) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13017221 | 0.83 | ADRA2A (0.76) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL5659141 | 0.81 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL7894000 | 0.81 | PTGIR (0.70) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL7886183 | 0.80 | PTGIR (0.73) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| SCHEMBL13017291 | 0.80 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CPTGIRGPR65 | |
| Hydrochloric Acid SCHEMBL4743710 | 0.79 | PTGIR (0.71) | ADRA2AADRA2BADRA2CPTGIRGPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194666-A1 | Combination Treatment Methods | MEDICAL RESEARCH COUNCIL (GB) | 2008-08-14 | — | — | US | claimed |
| WO-2006106311-A2 | COMBINATION TREATMENT METHODS FOR TREATING SEX-HORMONE DEPENDENT DISEASE AND FERTILITY TREATMENT | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2006-10-12 | — | — | WO | claimed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | claimed |
| EP-1596858-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | Medical Research Council (GB) | 2005-11-23 | — | — | EP | claimed |
| WO-2004071508-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2004-08-26 | — | — | WO | claimed |
| US-9321745-B2 | Inhibition of neovascularization by inhibition of prostanoid IP receptors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9295665-B2 | Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors | ALLERGAN, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2014143591-A9 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | ALLERGAN, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014143592-A1 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143591-A1 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275200-A1 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275238-A1 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2004071508-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2004-08-26 | — | — | WO | disclosed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | COURNOYER RICHARD LEO (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1265853-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2001-12-27 | — | — | US | disclosed |
| WO-2001068591-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-20 | — | — | WO | disclosed |
| EP-0902018-A3 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-02 | — | — | EP | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | ADRA2A 154/4885ADRA2B 69/4885ADRA2C 131/4885 |
| US-20140275200-A1 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | PTGIR, PTGER4, PTGIS | ADRA2A 324/4885ADRA2B 231/4885ADRA2C 779/4885 |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | ADRA2A 147/4885ADRA2B 72/4885ADRA2C 129/4885 |
| US-20080194666-A1 | Combination Treatment Methods | GNRHR, SHBG, FSHR | ADRA2A 632/4885ADRA2B 806/4885ADRA2C 1127/4885 |
| US-20140275238-A1 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS | PTGIR, PTGIS, PTGFR | ADRA2A 179/4885ADRA2B 135/4885ADRA2C 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.